MET and cancer: It is reasonable to hypothesize that, in future clinical settings, noninvasive imaging with PET and using these new tracers will support the diagnosis of c‐Met overexpressed cancers and the selection/evaluation (responding and nonresponding) of patients for c‐Met–targeting drugs.